These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 17606975)

  • 1. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
    Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
    J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
    Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
    J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
    Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
    J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
    Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
    J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
    Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
    J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.
    Aogi K; Rai Y; Ito Y; Masuda N; Watanabe J; Horiguchi J; Tokudome T; Takashima S
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1427-33. PubMed ID: 23536163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
    De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
    J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
    Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
    J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
    Pivot X; Villanueva C; Chaigneau L; Nguyen T; Demarchi M; Maurina T; Stein U; Borg C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):593-9. PubMed ID: 18363523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
    Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
    J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
    Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
    Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Vahdat LT; Vrdoljak E; Gómez H; Li RK; Bosserman L; Sparano JA; Baselga J; Mukhopadhyay P; Valero V
    J Geriatr Oncol; 2013 Oct; 4(4):346-52. PubMed ID: 24472478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies with epothilones for the treatment of metastatic breast cancer.
    Vahdat LT
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel cytotoxic agents: epothilones.
    Goodin S
    Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
    Ajani JA; Safran H; Bokemeyer C; Shah MA; Lenz HJ; Van Cutsem E; Burris HA; Lebwohl D; Mullaney B
    Invest New Drugs; 2006 Sep; 24(5):441-6. PubMed ID: 16586011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.